A recent extensive investigation has revealed that individuals grappling with both psychosis and Post-Traumatic Stress Disorder (PTSD) can safely and effectively achieve recovery through a specialized, integrated therapeutic approach. This groundbreaking study challenges long-held beliefs in the psychiatric community about the risks of addressing severe trauma directly in patients experiencing active psychosis symptoms.
The STAR (Study of Trauma And Recovery) trial, the largest multi-site randomized controlled trial of its kind, meticulously evaluated 305 participants across five United Kingdom locations over a span of five years. Historically, patients with psychosis have often been excluded from PTSD research due to clinicians' concerns that confronting traumatic memories could worsen their psychotic symptoms, such as hallucinations or delusions. However, the STAR study provides robust evidence that direct processing of trauma memories is not only safe but also highly beneficial for this vulnerable population.
Following nine months of integrated trauma-focused CBTp (Cognitive Behavioral Therapy for psychosis), a remarkable 50% of the treatment group no longer met the clinical diagnostic criteria for PTSD. This significantly contrasts with the control group, where just over 20% experienced similar improvements under standard care. The intervention also boasted an exceptionally low disengagement rate of merely 6.5%, underscoring the high acceptability of this tailored and flexible therapeutic framework among a complex and often heavily traumatized patient group.
Beyond PTSD remission, participants in the therapy group showed substantial improvements across a broad spectrum of clinical outcomes. Out of 27 assessed indicators, 22 demonstrated significant positive changes. These included moderate-to-large reductions in PTSD symptom severity, alongside notable decreases in depression, anxiety, suicidal ideation, paranoia, and multisensory hallucinations. The therapy's success in mitigating these diverse symptoms highlights its comprehensive impact on mental well-being.
This pioneering research was conducted by the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London, in collaboration with the South London and Maudsley NHS Foundation Trust (SLaM). Funded by the National Institute for Health and Care Research (NIHR), the findings were published in the esteemed journal The Lancet Psychiatry. The study's primary authors, Professor Emmanuelle Peters and Dr. Amy Hardy, emphasized that the results unequivocally demonstrate the safety and effectiveness of trauma-focused therapies for individuals with co-occurring PTSD and psychosis. They advocate for a paradigm shift in mental healthcare to ensure that those previously denied access to evidence-based trauma care can now receive it.
The success of the STAR trial is already paving the way for broader implementation. The intervention is actively being scaled up through the PICuP Clinic at SLaM. This initiative integrates individuals with lived experience who participated in the trial to co-deliver treatment training, effectively combating the internalized psychiatric stigma often faced by this patient group. This collaborative approach not only enhances the delivery of care but also empowers individuals with their recovery journeys.
One participant, Shane, who underwent the STAR therapy, now serves as a Peer-Support Worker at PICuP and collaborates on other research trials aimed at addressing internalized stigma. He shared that the therapy provided him with the necessary tools to comprehend and reshape his traumatic experiences, rebuilding trust, confidence, and a sense of connection. His testimony underscores the profound impact of this therapy in restoring a sense of control and belief in the possibility of recovery.
The STAR trial represents a critical advancement in the psychological treatment of a highly complex and marginalized population. It serves as a powerful call to action for commissioners and services to prioritize the implementation of trauma-focused CBTp, recognizing its potential to transform lives. The findings highlight an ethical imperative to ensure that clinical services and research do not inadvertently perpetuate the silence and suffering of trauma survivors through exclusion.
This groundbreaking research definitively establishes that trauma-focused Cognitive Behavioral Therapy for psychosis is a safe, widely accepted, and highly effective intervention for individuals experiencing both psychosis and PTSD. The previously underserved population, often excluded from such treatments, now has clear evidence supporting their access to psychological interventions designed to address the profound sequelae of their trauma.